This paper has highlighted such associations in the cases of the CCL22–CCR4 and CCL25–CCR9 axes, as well as for the CCR6, CCR10, XCR1, and CCRL2 receptors, suggesting that these chemokines and receptors could be potential therapeutic targets for anti-leukemia therapy. This evidence concerns the gene XCR1 and leukemia.